We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Stock in Hims & Hers Health was bound to tumble once it [could no longer sell]( ...
24/7 Wall St. on MSN2d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback